Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jay Achar

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Lancet (London, England)|November 10, 2016
WHO recommendations for multidrug-resistant tuberculosisCatherine Berry, Jay Achar, Philipp du Cros
Obstetric Medicine|October 13, 2015
Ebola viral disease and pregnancyBenjamin O Black, Séverine Caluwaerts, Jay Achar
ERJ Open Research|March 30, 2022
Programme costs of longer and shorter tuberculosis drug regimens and drug import: a modelling study for Karakalpakstan, UzbekistanStefan Kohler, Norman Sitali, Jay Achar, et al.
Journal of Public Health (Oxford, England)|November 23, 2022
Costs and import costs of past, present, and future TB drug regimens: a case study for Karakalpakstan, UzbekistanStefan Kohler, Norman Sitali, Jay Achar, et al.
PLOS Global Public Health|April 2, 2024
Correction: The contribution of drug import to the cost of tuberculosis treatment: A cost analysis of longer, shorter, and short drug regimens for Karakalpakstan, UzbekistanStefan Kohler, Norman Sitali, Jay Achar, et al.
PLOS Global Public Health|March 24, 2023
The contribution of drug import to the cost of tuberculosis treatment: A cost analysis of longer, shorter, and short drug regimens for Karakalpakstan, UzbekistanStefan Kohler, Norman Sitali, Jay Achar, et al.
Globalization and Health|June 25, 2024
Trends in the availability and prices of quality-assured tuberculosis drugs: a systematic analysis of Global Drug Facility Product Catalogs from 2001 to 2024Stefan Kohler, Jay Achar, Christiaan Mulder, et al.
Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace|January 20, 2021
Factors associated with time to sputum culture conversion of rifampicin-resistant tuberculosis patients in Klaipeda, Lithuania in 2016-2019: a cohort studySaulius Diktanas, Oleksandr Korotych, Yuliia Sereda, et al.
BMC Infectious Diseases|April 24, 2020
A case report of a child with probable drug resistant tuberculous pericarditis with a review of challenges involved in diagnosis, treatment and follow up of children with DR-TB pericarditisAravind Swaminathan, Philipp du Cros, Jay Achar, et al.
Plos One|November 25, 2020
Patient and health-care worker perspectives on the short-course regimen for treatment of drug-resistant tuberculosis in Karakalpakstan, UzbekistanShona Horter, Jay Achar, Nell Gray, et al.
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Lancet (London, England)|November 10, 2016
WHO recommendations for multidrug-resistant tuberculosisCatherine Berry, Jay Achar, Philipp du Cros
Obstetric Medicine|October 13, 2015
Ebola viral disease and pregnancyBenjamin O Black, Séverine Caluwaerts, Jay Achar
ERJ Open Research|March 30, 2022
Programme costs of longer and shorter tuberculosis drug regimens and drug import: a modelling study for Karakalpakstan, UzbekistanStefan Kohler, Norman Sitali, Jay Achar, et al.
Journal of Public Health (Oxford, England)|November 23, 2022
Costs and import costs of past, present, and future TB drug regimens: a case study for Karakalpakstan, UzbekistanStefan Kohler, Norman Sitali, Jay Achar, et al.
PLOS Global Public Health|April 2, 2024
Correction: The contribution of drug import to the cost of tuberculosis treatment: A cost analysis of longer, shorter, and short drug regimens for Karakalpakstan, UzbekistanStefan Kohler, Norman Sitali, Jay Achar, et al.
PLOS Global Public Health|March 24, 2023
The contribution of drug import to the cost of tuberculosis treatment: A cost analysis of longer, shorter, and short drug regimens for Karakalpakstan, UzbekistanStefan Kohler, Norman Sitali, Jay Achar, et al.
Globalization and Health|June 25, 2024
Trends in the availability and prices of quality-assured tuberculosis drugs: a systematic analysis of Global Drug Facility Product Catalogs from 2001 to 2024Stefan Kohler, Jay Achar, Christiaan Mulder, et al.
Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace|January 20, 2021
Factors associated with time to sputum culture conversion of rifampicin-resistant tuberculosis patients in Klaipeda, Lithuania in 2016-2019: a cohort studySaulius Diktanas, Oleksandr Korotych, Yuliia Sereda, et al.
BMC Infectious Diseases|April 24, 2020
A case report of a child with probable drug resistant tuberculous pericarditis with a review of challenges involved in diagnosis, treatment and follow up of children with DR-TB pericarditisAravind Swaminathan, Philipp du Cros, Jay Achar, et al.
Plos One|November 25, 2020
Patient and health-care worker perspectives on the short-course regimen for treatment of drug-resistant tuberculosis in Karakalpakstan, UzbekistanShona Horter, Jay Achar, Nell Gray, et al.
Pageof 4